Business View Magazine | February 2019

336 tion.Two of its products have already received an NPN number from Health Canada. Led by an out- standing team of industry professionals, Canntab has the experience and expertise needed to bring these products to market. Business ViewMagazine recently spoke with Canntab Therapeutics co-founders Jeff Renwick (CEO) and Richard Goldstein (CFO) about their firm’s history, innovative product development, and the role the company will play in the future of the cannabis industry.The following is an edited tran- script of that conversation. BVM: Can you give us the background on Canntab Therapeutics and its evolution to date? Goldstein: “About 11 years ago, Jeff Renwick,Tommy LaRocque (our current Procurement Director and Overseer of Operations), and I started a generic pharmaceutical company, and we created two generic pharmaceutical drugs for the United States. They’re both extended release drugs–very difficult to formulate.We licensed those two drugs to Am- neal, a multi-billion dollar American company that trades on the U.S. Stock Exchange.As it turns out, that generic pharmaceutical company we founded was the engine of the extended-release platform we are now using for our cannabis tablets. “About three years ago,we wanted to pursue the cannabis business, so we started a new company called Canntab Therapeutics In Cobourg,Ontario, and seeded it with fresh investment.We raised a lot of money last Jan. (2017) at 25 cents per share. Then,we raised over $5 million in subscription financing in Dec. (2017)–that’s where people put Jeff Renwick (CEO) and Richard Goldstein (CFO)